Latest Apolipoprotein E Stories

May have implications for the development of prevention therapiesWhat are the earliest brain changes associated with the risk of developing Alzheimer's disease? A scientific report published in the October Journal of Alzheimer's Disease finds reduced activity of an energy-generating enzyme in deceased young adult brain donors who carry a common genetic risk factor for Alzheimer's disease"”before the protein changes or microscopic abnormalities commonly associated with the disease and almost...

Participants included individuals who carry a high-risk genePhysical activity promotes changes in the brain that may protect high-risk individuals against cognitive decline, including development of Alzheimer's disease, according to a new study done at the University of Wisconsin-Milwaukee (UWM).J. Carson Smith, an assistant professor of health sciences, included in the study both people who carry a high-risk gene for Alzheimer's disease, and other healthy older adults without the...

ApoE4 causes GABAergic interneuron impairment, leading to learning and memory deficitsAlzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65󈞼% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.Scientists at the Gladstone Institutes of...

SLU Geriatrician Collaborates on Year-Long Study of Chinese Older MenLow levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist."Having low testosterone may make you more vulnerable to Alzheimer's disease," said John E. Morley, M.D., director of the division of geriatric medicine at Saint Louis University and a study co-investigator. "The...

BROOMFIELD, Colo., Oct. 5 /PRNewswire/ -- Accera, Inc., a medical research and development company delivering breakthrough therapies for serious diseases such as Alzheimer's disease (AD), announced today that Thomas Werner, Ph.D., has been appointed President and CEO. Concurrently with Dr. Werner's appointment, the U.S. Food and Drug Administration (FDA) has accepted Accera's Investigational New Drug (IND) application to conduct a phase 2-3 clinical study in patients with mild-to-moderate...

(Ivanhoe Newswire) -- Biomarkers in blood serum can be combined with clinical information to accurately classify patients with Alzheimer's disease.  If only biomarkers in blood serum could make our tax forms easier and more accurate."There is clearly a need for reliable and valid diagnostic and prognostic biomarkers of Alzheimer's disease, and in recent years, there has been an explosive increase of effort aimed at identifying such markers," which authors from the study are...

An initial analysis suggests that biomarkers in blood serum can be combined with clinical information to accurately classify patients with Alzheimer's disease, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals."There is clearly a need for reliable and valid diagnostic and prognostic biomarkers of Alzheimer's disease, and in recent years, there has been an explosive increase of effort aimed at identifying such markers," the...

- - New Alzheimer's Risk Gene May Affect Memory Scores and Brain Atrophy in Middle Age - - Clinical Trial of Intranasal Insulin Shows Benefits in Alzheimer's and MCI - - Known Alzheimer's Risk Gene May Change Shape of Brain Deposits - HONOLULU, July 14 /PRNewswire-USNewswire/ -- Last minute scientific submissions to the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI, known as "hot topics," suggest that (1) a newly-discovered risk...

HONOLULU, July 13 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations. This research indicates there may be potential for an increased risk of comorbid conditions, such as seizures, stroke and type 2 diabetes,...

By investigating the association between genetic loci related to Alzheimer's disease and neuroimaging measures related to disease risk, researchers may have uncovered additional evidence that several previously studied genetic variants are associated with the development and progression of Alzheimer's disease and also may have identified new genetic risk factors for further study, according to a report in the June issue of Archives of Neurology, one of the JAMA/Archives journals."The...